​

The GTC's underpinning platform technology for the Portfolio is a viral gene therapy platform based on the rSIV.F/HN lentiviral vector which will be applied to five projects: Influenza A, ​Pulmonary Fibrosis (PF), α1 Anti Trypsin Deficiency (AATD)​, ​Haemophilia and Surfactant Protein B (SP-B) deficiency.

​

You can find out more about the work we have undertaken 

​​

​

​